Biotech

Biotechs Propel February to Record Month for CMPOs

Emerging growth companies raised $663.6 million in 18 confidentially-marketed public offerings (CMPOs) in February, making it the most actively used registered private placement structure for the month, and the most active month for CMPOs in over 18 months. Biotech issuers fueled the deal activity, raising 62% of the capital and launching half of the CMPO deals closed last month. February’s CMPO activity was at the highest levels in the past 24 months in terms of total deals and capital raised. The month’s deal pace was well ahead of 2013’s monthly average of 10 deals raising $359 million. It was the best month for CMPOs since October 2012, when 13 deals were closed raising $520 million.

SEC

Reg A+ Moves Toward Adoption

With the comment period in full-swing on the SEC’s proposed rule expanding Reg A to allow companies to conduct “mini-IPOs” of up to $50 million without filing a traditional S-1 registration statement, supporters and critics of “Reg A+” are using the proposal as a vessel that is being filled with the hopes and fears of a generation of frustrated securities professionals and regulators. Small cap bankers and deal attorneys see the proposal as the first real opportunity to revive the moribund under-$100 million IPO market for the first time since the mid-1990s, when a series of mostly well-intended anti-fraud and securities trading reforms conspired to nearly eliminate small public offerings in the U.S. They have imbued the proposal with the potential to bring forth a cornucopia of mini-IPOs, mini-SPACs, and mini-REITs that will stimulate public investment in new companies at rates unseen in nearly two decades. State regulators, led by the North American Securities Administrators Association (NAASA), fear Reg A+ as proposed, with its blanket federal pre-emption of state securities laws, will blast a hole through the patchwork of state-level investor protection laws aimed at stanching penny stock fraud. They fear a return to the days when stock grifters moved about the country freely offering unregistered Reg D 504 shares in shell companies, and syndicated partnership stakes in mining claims and oil and gas leases, with no oversight and little truthful disclosure, let alone investment legitimacy. The 50 State Solution
With the comment period on Reg A+ at the halfway point to its March 24 close, the NAASA leadership, represented by Bill Galvin, Massachusetts’ Secretary of the Commonwealth, and Jack Herstein of the Nebraska Department of Banking and Finance, continue to argue for a multi-state “coordinated review system” to regulate and review Reg A offerings at the state level.

SEC

Secondary Market Key to Success of New Reg A+ Offerings

The development of a reasonably liquid secondary market for trading securities issued under the newly reformed Regulation A exemption proposed by the Securities and Exchange Commission is critical to the future growth and success of the offering structure for raising emerging growth capital, say both its proponents and critics. Without one, many cap markets pros say the new Tier II “A+” offerings will offer few advantages over the standard S-1 registered offerings while incurring most of the costs, and continue to be the neglected stepchild of the public offerings market. But with a secondary market to facilitate investor exits, Reg A+ boosters see a Goldilocks-like equity offering structure that could become the go-to channel to bridge young private emerging growth companies, some of them financed via publicly marketed private offerings, into the public markets. The SEC published a draft of the reformed Reg A rules in late December as an amendment to the Securities Act labeled Section 3(b)(2).  The proposal splits Reg A offerings into Tier I and Tier II types.

Life Science Issuers Crowd the Best and Worst Performing Deals of Year

The volatile biotech sector dominates the year’s top 40 best and worst performing growth equity private placement (EPP) deals, as investors prove the adage that a good hit will take you far – as well as its converse, that a miss can be devastating. Outside of life sciences companies, internet media and alternative energy companies rewarded investors while conventional energy and mining companies proved treacherous. Registered and unregistered EPPs by biotech, healthcare and pharmaceutical development companies comprise 46% of the best and worst performing deals by emerging growth companies in 2013, according to data compiled by Sagient Research and analyzed by Growth Capital Investor. (For the complete list of best and worst deals, see pages 12-13 of the current issue of Growth Capital Investor.)

Life science issuers closed 44 out of 80 combined best performing registered and unregistered private placements as of December 15. They also closed 30 of the 80 worst performing deals to date in 2013.